Psychiatry - December 2008 - (Page 59)

[research to practice] her personal background, which may require clinicians to gather substantial amounts of historical information. This may be fairly burdensome to some clinicians, but will help frame a patient’s current cognitive ability: Is it a lot worse than expected? Or is it about where it should be given the person’s family, personal, and educational history? patients for rehabilitation as necessary. If ongoing studies on new compounds to improve cognition are fruitful, clinicians will thus be in a good position to use these medications and assess their efficacy in the clinic. Durham, North Carolina. Dr. Keefe is also on the editorial board of Psychiatry 2008. FINANCIAL DISCLOSURES: Dr. Targum has stock or stock options in BrainCells Inc. and Prana Biotechnology Ltd. In the past year, Dr. Targum has been a consultant to United BioSource Corporation, Dynogen, Epix, DOV Pharmaceuticals, Sepracor, NuPathe, and Memory Pharmaceuticals. In the past year, Dr. Keefe has received grant/research support from Eli Lilly and Pfizer. He has received honoraria or served as a consultant or advisory board member for Abbott Pharmaceuticals, Acadia, BiolineRx, Bristol Myers Squibb, Cephalon, Cortex, Dainippon Sumitomo Pharma., Eli Lilly, Johnson & Johnson, Lundbeck, Memory Pharmaceuticals, Merck, Neurosearch, Orexigen, Pfizer, Sanofi/Aventis, Shering-Plough, Wyeth, and Xenoport. In addition, Dr. Keefe receives royalties from the Brief Assessment of Cognition in Schizophrenia (BACS) testing battery and the MATRICS Battery (BACS Symbol Coding). ADDRESS CORRESPONDENCE TO: Dr. Steve Targum, Oxford BioScience Partners, 222 Berkeley Street, Suite 1650, Boston, MA 02116; E-mail: sdtargum@yahoo.com REFERENCES 1. Keefe RS, Fenton WS. How should DSM-V criteria for schizophrenia include cognitive impairment? Schizophr Bull. 2007;33(4):912–920. Nuechterlein KH, Green MF, Kern RS, et al. The MATRICS consensus cognitive battery: Part 1. Test selection, reliability, and validity. Am J Psychiatry. 2008;165:203–213. DR. KEEFE, WHAT DO YOU SEE ON THE HORIZON FOR NEUROCOGNITIVE STUDIES IN SCHIZOPHRENIA? Dr. Keefe: Cognition will increasingly be involved as a crucial assessment in research and clinical practice. Researchers have known for a long time that cognition is at the core of the disorder, and it is likely that it will be represented in DSM-V and ICD-11. It has become very clear that good functioning depends upon cognitive ability and that treatments that can improve cognition are needed. Astute clinicians have begun to incorporate cognitive measures into their practices so that they can adjust doses of medications or refer 2. AUTHOR AFFILIATIONS: Dr. Targum is an executive-in-residence at Oxford BioScience Partners and on the faculty of the Department of Psychiatry at the Massachusetts General Hospital. Dr. Targum is chief medical officer at BrainCells Inc., and chief medical advisor to Prana Biotechnology Ltd. Dr. Targum is on the editorial board of Psychiatry 2008. Dr. Keefe is Professor of Psychiatry and Behavioral Sciences, Duke University Medical Center [VOLUME 5, NUMBER 12, DECEMBER] Psychiatry 2008 59

Table of Contents Feed for the Digital Edition of Psychiatry - December 2008

Psychiatry - December 2008 Editor’s Message Contents Editorial Advisory Board Antidepressant Prescribing by Specialty and Treatment of Premenstrual Dysmorphic Disorder Pain, Pain, Go Away: Antidepressants and Pain Management Why Psychotherapy Helps the Patient in Chronic Pain General Medical Drugs Associated with Depression Katatonia: A New Conceptual Understanding of Catatonia and a New Rating Scale Thermoregulation and the Role of Calcium Signalling in Neurotransmission Cognition and Schizophrenia: Is There a Role for Cognitive Assessments in Diagnosis and Treatment? Journal Watch Information for Authors

Psychiatry - December 2008

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.